Get started
Author

Ryan T. Bushey

ORCID: 0000-0003-2497-4953
Observed ORCID: 0000-0003-2497-4953
OpenAlex ID: A5082829084
Complement factor H: a novel innate immune checkpoint in cancer immunotherapy
2024 · Ruchi Saxena, Elizabeth B. Gottlin, et al. · Frontiers in Cell and Developmental Biology · 29
PDF
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
2023 · Ryan T. Bushey, Ruchi Saxena, et al. · Molecular Cancer Therapeutics · 24
PDF
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody
2024 · Ruchi Saxena, Ryan T. Bushey, et al. · The Journal of Immunology · 18
Tumor-Derived Complement C3 Overexpression in STK11 -Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al. · Cancer Immunology Research · 3
Figure S5 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Table S1 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S2 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S3 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S10 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Table S2 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S8 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S7 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Data from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S4 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S1 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S6 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S9 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Table S3 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026 · Sora Suzuki, Bojidar Kandar, et al.
Figure S1 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
2025 · Ryan T. Bushey, Ruchi Saxena, et al.
PDF
Figure S5 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
2025 · Ryan T. Bushey, Ruchi Saxena, et al.
PDF
Figure S3 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
2025 · Ryan T. Bushey, Ruchi Saxena, et al.
PDF
Table S1 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
2025 · Ryan T. Bushey, Ruchi Saxena, et al.
Table S2 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
2025 · Ryan T. Bushey, Ruchi Saxena, et al.
Figure S2 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
2025 · Ryan T. Bushey, Ruchi Saxena, et al.
PDF
Figure S4 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
2025 · Ryan T. Bushey, Ruchi Saxena, et al.
PDF
Works count: 49
Citation count: 74
H-index: 3
I10-index: 3
Year
Topic
Type